Data to highlight PTC-2105’s attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos’s lead clinical candidate in development for elderly patients with
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)"Speedy," a
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicineEos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIXFRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
NEW YORK, July 10, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Announced merger agreement with Eos SENOLYTIX in MarchClosed private placement of preferred stockFRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company")
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseaseFRAMINGHAM, Mass.
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix
Plans to License or Monetize our Migraine and Inhalation Assets ContinueFRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical
